An article published in Medscape discusses the policies recently adopted in different European countries regarding the management of gender dysphoria in minors. These policies are mostly being redirected towards a more psychologically supportive approach and warn of the dangers of using hormone blockers at an early age.

Medscape is one of the leading online reference sites for doctors and healthcare professionals.

Puberty blockers approved for the treatment of precocious puberty are being used in minors with gender dysphoria to stop or delay the adolescent maturation process. Their purpose is to reduce the sexual differentiation characteristic of this stage with a view to subsequent surgical gender transition.

The side effects associated with these treatments are very worrying and, in many cases, irreversible. Although some activists and transgender associations advocate their use, medical evidence shows that they are not safe and seriously questions their effectiveness.

In the United Kingdom, the Cass Review final report was published in April 2024. The report carried out by Dr Hilary Cass was prompted by the considerable increase in demand for gender identity treatments among children and adolescents.

Dr Cass, former president of the Royal College of Paediatrics and Child Health, found “remarkably weak evidence” to support gender treatments for children.

In March, England’s National Health Service (NHS) announced it would no longer prescribe puberty blockers to children at gender identity clinics due to a lack of evidence supporting their safety or effectiveness.

On April 18, Scotland’s only gender clinic reported that it had also stopped prescribing puberty blockers to under-18s and that new underage patients would no longer receive other hormonal treatments.

It should be recalled that in March 2023, the British government vetoed the Scottish gender law that facilitated gender transition at age 16. This law lowered the minimum age for gender reassignment from 18 to 16 and eliminated the need to present a medical report along with evidence confirming having lived at least 2 years with that intention.

In Germany, Alexander Korte, a child psychiatrist at Ludwig Maximilian University of Munich, said that “I consider this therapy irresponsible because of the unclear data situation. If opposite-sex hormones are used after the puberty blockers, which is known to be the case in over 95% of children treated with GnRH [gonadotropin-releasing hormone] analogs, this leads to permanent infertility in addition to permanent impairment of the ability to experience sexuality.”

In Finland, Dr. Riittakerttu Kaltiala said puberty blockers can only be considered for use after a multidisciplinary evaluation at one of the nationally centralized gender identity units for minors.

In the Netherlands the guidelines have not yet been revised. However, in February 2024, the Parliament ordered that an investigation be conducted into the physical and mental health outcomes of children prescribed puberty blockers.

In Norway, the Healthcare Investigation Board (Ukom) recommended in 2023 that the Ministry of Health and Care commission the Directorate of Health to revise the national guideline for gender incongruence so that it is based on a systematic summary of available evidence. The Ukom report recommended that puberty blockers and hormonal and surgical gender reassignment treatment for children and young people should be defined as experimental treatments.

In France, the National Academy of Medicine recommended in 2022 “greatest reserve” regarding the use of puberty blockers in children and adolescents. However, if they have parental authorization, puberty blockers can still be prescribed to them.

In Sweden, the National Board of Health and Welfare stated in 2022 that the risks of puberty blockers and gender reassignment hormone treatments for people under 18 years outweighed their potential benefits.

Despite this, it added that hormone treatment should continue to be administered, but within a research framework to better understand its impact on gender dysphoria, mental health and quality of life in this age group. And that in exceptional cases the treatment could be continued.

In Spain, the Law for the Equality of Trans People and the Guarantee of LGBTI Rights prescribes medication with puberty blockers and legal sex change from the age of 12, ignoring experts’ warnings about the serious risks of this practice.

Suicide risk

A recent article analyzes the prevalence of suicide risk and self-harm in people who have undergone sex reassignment surgery. The study takes patient data from TriNeX with a sample of 15.6 million people in the United States and analyzes data spanning 20 years (2003-2023).

The sample consists of four cohorts of people aged 18-60: Cohort A is made up of patients who have undergone a sex reassignment operation, cohort B are patients who have not undergone surgery to change their sex, cohort C are people who have had a tubal ligation or a vasectomy and cohort D are people who have had pharyngitis.

After analyzing the suicide risks of patients in the four cohorts, the study concludes that people who had undergone sex reassignment surgery have a risk 12 times higher than people who had not had surgery.

As we have recently published in our Observatory, a new paper published in BMJ Mental Health questions the effectiveness of gender transition interventions as a method to prevent suicidality in people affected by gender dysphoria.

This evidence has been highlighted in previous studies for years. Thus, an article published in 2011 already concluded that there are substantially higher rates of mortality, death from cardiovascular disease, suicide and psychiatric hospitalizations in transsexuals with sex reassignment compared to a healthy control population.

Bioethical assessment

Addressing the problem of gender dysphoria requires, as in all good medical practice, rigorous recourse to the available scientific evidence, which shows the risk/benefit relationship of the different therapeutic options. Their scrupulous analysis will make it possible to undertake or withdraw treatments according to their evolution, results, side effects or efficacy.

Thus, it is common for therapeutic standards of approved treatments to be rectified, or for them to end up being suspended or modified due to the lack of evidence of a clearly positive benefit/risk balance.

In the case of treatments with puberty blockers for children and adolescents with gender dysphoria, it must be clarified that there are no authorizations approved by the competent bodies for this use and their use is called “off label”.

One of the reasons that has been given for applying unauthorized treatments is their alleged ability to reduce the risk of suicide or suicidal ideation in those affected, which is what is now strongly questioned.

But in addition to the fact that the evidence on their effectiveness for this purpose is increasingly weak and questionable, data is accumulating on the undesirable effects associated with these treatments, which are in many cases irreversible, as has already been stated.

Some healthcare professionals, scientific societies and regulatory bodies modify the indication and application criteria of these treatments in response to the need to address the available scientific evidence, as required by good medical practice.

There are serious questions that have not been properly answered and which we raise as a conclusion: Why were these treatments initiated and universalized if there was no solid evidence to support them? Why have the data that strongly question their efficacy and safety been ignored or not adequately evaluated?

And, finally, why have countries such as Spain not undertaken any modification to the law regulating these interventions? The so-called Trans Law is imprudent, interventionist, inconsistent and maleficent. And it is so because it does not consider scientific evidence, nor does it follow the criteria of good medical practice.

The answers to these questions will probably not be found in the scientific field, but in the ideological field. And we regret this because the consequences of malpractice are detrimental to the health of those affected and their right to receive quality care, accompanied by sufficient, contrasted and updated information.

Julio Tudela

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

Share This Story, Choose Your Platform!